For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Rituximab - Immune thrombocytopenia
PAD Profile : Rituximab - Immune thrombocytopenia
Traffic Light Status
Status 1 of 2.
- Not Specified
Status 2 of 2.
- Not Specified
Guidelines
No guidelines returned.
Other Drugs
Other Indications
- Refractory vasculitis
- Rheumatoid arthritis
- Systemic Lupus Erythematosus
- Sjogren's syndrome
- Chronic inflammatory demyelinating polyneuropathy
- Any paediatric use
- ANCA-positive vasculitis
- Connective tissue disease
- Graft versus Host Disease (GVHD)
- Myositis
- Immunoglobulin G4 related disease
Additional Documents
No additional documents returned.
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves the updated ITP pathway.
ITP treatment pathway has been updated to include sequential use of eltrombopag & romiplostim
The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends to prescribe biological products by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist. Https://www/gov/uk/drug-safety-update/biosimilar-products
Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.
Associated BNF Codes
No BNF codes returned.